Ozempic Reduces Breast Cancer Risk by 30%. Here's What That Actually Means.

Two studies presented at the 2026 American Society of Clinical Oncology Annual Meeting found that GLP-1 drugs significantly reduce both breast cancer incidence and metastatic progression. Here's what the evidence actually shows — and what it does not yet prove.

GLP-1 receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide — have spent the past three years generating headlines primarily about weight loss. The evidence accumulating around them in oncology is becoming impossible to ignore.

Two separate studies presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago add significant weight to the case that GLP-1 drugs may be doing something important in breast cancer specifically — not just through the weight loss pathway, but potentially through direct mechanisms involving GLP-1 receptors expressed in tumour tissue.

Both studies are observational. Neither proves causation. A clinical trial is being planned. Here is what the evidence actually shows — and why it has prompted that trial.

TL;DR

• A study of 111,646 women presented at ASCO 2026 and published in JCO Oncology Practice found that GLP-1 drug users had approximately 30% lower odds of developing breast cancer compared with non-users. In the matched cohort, 1.62% of GLP-1 users were diagnosed versus 2.31% of non-users — an absolute difference of approximately seven fewer cancers per 1,000 women.
• A second ASCO 2026 study found GLP-1s reduced metastatic progression in breast cancer by 45% compared with a gliptin control group — and that high GLP-1 receptor expression in breast tumours was associated with 45% lower risk of death.
• Both studies are observational and cannot confirm causation. A multisite clinical trial is being planned to test whether GLP-1 medications can lower breast cancer incidence in high-risk women.
• The protective mechanism is likely multiple. Weight loss reduces the oestrogen excess produced by adipose tissue — a key driver of hormone receptor-positive breast cancer. Anti-inflammatory effects reduce the chronic inflammation that promotes tumour growth. And direct GLP-1 receptor signalling in tumour tissue may play an independent role.
• The study only included women with BMI 25 or above. The findings do not apply to women of healthy weight.
• Breast cancer is the most common cancer among UK women — around 55,000 new cases a year. Excess weight is one of the few modifiable risk factors. If the GLP-1 protective effect is confirmed in clinical trials, the public health implications are substantial.

The Penn Medicine Study: What It Found

The primary study was led by Dr Elizabeth McDonald, a professor of radiology at the University of Pennsylvania Perelman School of Medicine and a practising breast radiologist at Penn's Abramson Cancer Center. It analysed electronic health records from 111,646 women aged 45 to 80 with a BMI of 25 or above who had breast imaging and a documented outcome within the Penn Medicine health system between January 2022 and June 2025.

Among the participants, 15,264 women — 13.7% — had documented prescriptions for GLP-1 medications. The remaining 86.3% had no documented GLP-1 exposure.

The results were consistent across two analytical approaches. In the full unmatched cohort, GLP-1 users had 35% lower odds of breast cancer diagnosis. In a propensity-score matched cohort — designed to control for confounding variables — GLP-1 users had 30.5% lower odds.

The absolute figures matter as much as the relative ones. In the matched cohort, 1.62% of GLP-1 users were diagnosed with breast cancer during the study period versus 2.31% of non-users — an odds ratio of 0.70. The absolute difference was 0.69 percentage points, or roughly seven fewer cancers per 1,000 women.

Seven fewer cancers per 1,000 women is a modest absolute effect. Across the millions of women in the UK who are overweight and potentially eligible for GLP-1 prescriptions, the population-level implications are considerably larger. Whether the effect is real — rather than a residual confounding artefact of an observational study — is precisely what the planned clinical trial will determine.

> While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it's worth investigating these weight-loss drugs as potential cancer prevention tools.

> — Dr Elizabeth McDonald, University of Pennsylvania

The Second ASCO Study: Metastatic Progression and Tumour Receptors

The second study presented at ASCO 2026 adds a mechanistically important dimension to the first.

This study used real-world data to compare the effects of GLP-1s and DPP-4 inhibitors on cancer progression for seven obesity-related cancers including breast cancer, in 12,112 people from the TriNetX database who had cancer at stage I, II, or III. Half had started a GLP-1 drug after their cancer diagnosis. Half had started a gliptin.

For breast cancer, the GLP-1 group had a 10% rate of metastatic progression compared with 20% in the gliptin group — a 45% reduction. For colorectal cancer: 13% versus 22%. For liver cancer: 19% versus 28%.

The most mechanistically significant finding was the tumour receptor data. High GLP-1 receptor expression in tumours was associated with a 33% lower risk of death overall — and for breast cancer specifically, a 45% lower risk of death. The association of high GLP-1R expression with better survival suggests that GLP-1 signalling may be involved in the progression of these cancers — and therefore that GLP-1 drugs may be protective through a direct mechanism rather than simply through weight loss.

This is the finding that changes the character of the research question. If GLP-1 receptors are expressed in breast tumour tissue and their activation is associated with better outcomes, the protective effect of GLP-1 drugs may not be entirely mediated by weight loss — it may involve direct anti-tumour signalling.

The Mechanism: Why GLP-1 Drugs Might Protect Against Breast Cancer

The mechanism behind GLP-1's potential breast cancer protective effect is likely multiple — and separating the weight loss pathway from the direct receptor pathway is one of the key objectives of the planned clinical trial.

The weight loss pathway is the most established. Obesity is a well-established risk factor for breast cancer, particularly hormone receptor-positive breast cancer in postmenopausal women. The mechanism is oestrogen: adipose tissue — body fat — is a major source of oestrogen production after the menopause, through aromatase enzymes that convert androgens to oestrogen. More adipose tissue produces more oestrogen. More oestrogen stimulates oestrogen receptor-positive breast cell proliferation. GLP-1 drugs produce sustained, significant weight loss — and by reducing adipose tissue, they reduce the oestrogen excess that drives the most common type of breast cancer.

The anti-inflammatory pathway operates alongside weight loss. Obesity exacerbates tumour progression through hormonal imbalance, chronic inflammation, and adipokine and insulin signalling — all targets that may be modifiable through weight reduction. Chronic low-grade inflammation — a consistent feature of obesity — promotes the tumour microenvironment that supports cancer cell survival and proliferation. GLP-1 drugs have anti-inflammatory effects beyond their weight loss effects, potentially reducing this tumour-promoting environment independently.

The direct GLP-1 receptor pathway is the most mechanistically novel. GLP-1 receptors are expressed in various tissues beyond the pancreas — including in cardiac tissue, the kidney, and apparently in breast tumour cells. The finding that high GLP-1 receptor expression in breast tumours is associated with 45% lower cancer mortality suggests that GLP-1 signalling in tumour tissue may directly inhibit tumour progression. The specific mechanism is not yet established — it may involve effects on cancer cell proliferation, apoptosis, or the tumour immune microenvironment.

> GLP-1 medications are intriguing from a cancer research perspective because they weren't designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we're eager to study them in this context.

> — Dr Elizabeth McDonald, University of Pennsylvania

What This Does Not Show

The limitations of the evidence are as important as the findings — and are clearly stated by the researchers themselves.

Causation is not established. Both studies are observational — they identify associations between GLP-1 drug use and reduced breast cancer outcomes, but they cannot confirm that the drugs caused the reduction. Women prescribed GLP-1 drugs may differ from non-users in ways that affect breast cancer risk and that the statistical matching cannot fully account for.

The study only included overweight and obese women. The 111,646-woman Penn Medicine study required a BMI of 25 or above for inclusion. The findings do not apply to women of healthy weight — and should not be extrapolated to them. The obesity-breast cancer relationship is the biological basis for the hypothesised protective effect. That basis does not exist in the same way for women without excess weight.

The absolute risk reduction is modest. Seven fewer cancers per 1,000 women is meaningful at a population level but not a dramatic individual-level risk reduction. It is not the effect size of tamoxifen in high-risk women. It is a signal that warrants investigation rather than a confirmed benefit that warrants prescribing.

The follow-up period is short. The Penn Medicine study covered January 2022 to June 2025 — a maximum of three and a half years. Breast cancer risk reduction from lifestyle and pharmacological interventions typically requires longer observation periods to assess with confidence.

The Clinical Trial Being Planned

The strength of the observational evidence has prompted action. Plans are underway for a multisite clinical trial to assess whether GLP-1 medications can lower breast cancer incidence among high-risk women — including those with a previous history of the disease.

The TMIST study — which has recruited approximately 109,000 women worldwide, with 21% African Americans in the US cohort — has been identified as a well-characterised population ideally suited to study the preventive effects of GLP-1 drugs in a prospective trial.

The clinical trial will be the test. Until it reports, the observational evidence is compelling enough to have triggered it — but not sufficient to change clinical practice.

What the UK Breast Cancer Picture Looks Like

Breast cancer is the most common cancer in the UK — around 55,000 new cases diagnosed each year, approximately one in seven women over their lifetime. Excess weight is one of the few modifiable risk factors for breast cancer. Around 63% of UK adults are overweight or obese.

The existing pharmacological prevention options are limited. Tamoxifen and anastrozole are recommended for women at high risk — but uptake among eligible women is limited because of known side effects. If the GLP-1 protective effect is confirmed in clinical trials, it would represent a meaningful addition to the prevention landscape — a drug already prescribed at scale for weight management that may simultaneously reduce breast cancer incidence.

The broader oncology picture from ASCO 2026 adds to this: GLP-1s may reduce metastatic progression across multiple obesity-related cancers — lung, breast, colorectal, and liver. This is not a single-cancer story. It is the beginning of an oncological research programme around a drug class that was designed for diabetes and found to do considerably more.

Frequently Asked Questions

Do GLP-1 drugs like Ozempic reduce breast cancer risk? A large observational study presented at ASCO 2026 and published in JCO Oncology Practice found that women with a BMI of 25 or above who were taking GLP-1 medications had approximately 30% lower odds of developing breast cancer than matched non-users. The absolute difference was approximately seven fewer cancers per 1,000 women. The study is observational and does not confirm causation. A clinical trial is being planned to test whether the association reflects a true protective effect.

Why might GLP-1 drugs reduce breast cancer risk? Multiple mechanisms are proposed. Weight loss reduces the oestrogen excess produced by adipose tissue — a key driver of hormone receptor-positive breast cancer. Anti-inflammatory effects reduce chronic inflammation that promotes tumour growth. And a second ASCO 2026 study found GLP-1 receptors are expressed in breast tumour tissue and that high receptor expression is associated with 45% lower cancer mortality — suggesting a direct anti-tumour mechanism beyond weight loss.

Does this mean women should take Ozempic to prevent breast cancer? No — the evidence is observational and does not yet confirm causation. A clinical trial is being planned. Current prescribing guidelines do not recommend GLP-1 drugs for breast cancer prevention. Women concerned about their breast cancer risk should speak to their GP about risk assessment and existing prevention options.

Who was included in the study? Women aged 45 to 80 with a BMI of 25 or above who had breast imaging within the Penn Medicine health system between January 2022 and June 2025. The findings apply to overweight and obese women in this age range — they should not be extrapolated to women of healthy weight.

What is the absolute risk reduction? In the matched cohort, 1.62% of GLP-1 users were diagnosed with breast cancer versus 2.31% of non-users — an absolute difference of 0.69 percentage points, or approximately seven fewer cancers per 1,000 women. The relative risk reduction of 30% is the more commonly reported figure but the absolute difference is the more practically meaningful one at an individual level.

What other cancers might GLP-1 drugs affect? A second ASCO 2026 study found GLP-1s reduced metastatic progression in breast cancer by 45%, colorectal cancer by approximately 40%, and liver cancer by approximately 32% compared with a gliptin control group. GLP-1 receptor expression in tumours was associated with 33% lower risk of death overall. The research is preliminary but suggests GLP-1 drugs may have broader oncological effects across multiple obesity-related cancers.

The Bottom Line

Two studies presented at ASCO 2026 have significantly advanced the case that GLP-1 drugs may be doing something important in breast cancer — through weight loss, through anti-inflammatory effects, and potentially through direct GLP-1 receptor signalling in tumour tissue.

The 30% relative risk reduction in breast cancer incidence is a compelling signal from a large observational study. The 45% reduction in metastatic progression and the tumour receptor findings add mechanistic depth. Neither study proves causation. Both studies justify the clinical trial that is now being planned.

The honest message for women currently taking GLP-1 drugs for weight management is that the emerging oncological evidence is an additional reason to feel positive about the decision — not a reason to start the drugs specifically for cancer prevention. And the honest message for those not currently taking them is that the evidence is promising and developing, and worth watching as the clinical trial proceeds.

For the broader evidence on what GLP-1 drugs do beyond weight loss — cardiovascular protection, cognitive benefits, addiction research, and now oncology — read our full piece on GLP-1 benefits beyond weight loss: GLP-1: The Benefits Beyond Weight Loss.

Related reading: GLP-1: The Benefits Beyond Weight Loss · Does Collagen Actually Work? The Largest Study Yet Has an Answer · The £4 Drug That Scientists Think Could Slow Ageing

Popular Articles